Kyprolis is a prescription drug used to treat certain types of multiple myeloma in adults. It’s prescribed for this condition in certain situations. To learn more, see “Is Kyprolis used for ...

Kyprolis (carfilzomib) is a prescription brand-name medication. It’s approved by the Food and Drug Administration (FDA) to treat multiple myeloma in adults in certain situations. Kyprolis can ...

has accepted for priority review the supplemental New Drug Application (sNDA) of Kyprolis (carfilzomib) for Injection for the treatment of patients with relapsed multiple myeloma who have received ...

to the Food and Drug Administration (FDA) for Kyprolis (carfilzomib) for Injection for the treatment of patients with relapsed multiple myeloma, who has received at least one prior therapy.

Kyprolis has interactions with some other drugs. Examples include combined hormonal birth control and clozapine. Kyprolis is prescribed for relapsed or refractory multiple myeloma in adults who ...

Amgen Inc. and its subsidiary Onyx Pharmaceuticals said on Wednesday that their Kyprolis cancer drug failed to meet its primary endpoint of improving overall survival for patients with relapsed ...

Amgen Inc.AMGN-0.75%decrease; red down pointing triangle said the U.S. Food and Drug Administration granted approval for its Kyprolis combination therapy as a second-line treatment for patients ...

March 1 (Reuters) - Amgen Inc's Kyprolis helped patients with relapsed multiple myeloma live twice as long before their blood cancer worsened compared to a regimen containing rival drug Velcade ...

Kyprolis (carfilzomib) received the Food and Drug Administration's (FDA) approval today for treating multiple myeloma patients who have had at least two prior therapies, including Velcade (bortezomib) ...

The committee also ruled that Kyprolis was not an “end of life” drug, as patients in this stage of the disease were likely to live longer than 24 months on existing treatments. In its document ...

Blood-cancer drug Kyprolis outperformed standard treatment in a late-stage trial testing the drug in patients with multiple myeloma, said Amgen, a result that fueled the biotech’s oncology aspirations ...

(HealthDay) -- Kyprolis (carfilzomib) has been approved by the U.S. Food and Drug Administration to treat certain people with multiple myeloma who have already been given at least two prior therapies.